Objectives-To evaluate the diagnostic performance of contrast-enhanced sonography for characterization of the lymph node status (metastatic or not) in patients with breast carcinomas by comparison with sentinel lymph node biopsy.
I
n reducing breast cancer morbidity and mortality, a pivotal aspect is the accurate analysis of prognostic factors. Among them, the lymph node status has the strongest influence on long-term survival. Several studies [1] [2] [3] [4] have highlighted that the node parameter is essential for predicting the natural history of breast cancer; therefore, inspecting axillary lymph nodes for metastasis is the first step in breast tumor staging. In the past, such information was gathered by complete axillary clearance, although this procedure entails various side effects, such as lymphedema, arm paresthesia, and shoulder motion restriction.
Sentinel lymph node biopsy 5, 6 is the current reference-standard test for studying the node parameter in breast carcinoma and has replaced axillary clearance. 5, 6 In 97% of cases, 7 sentinel lymph node biopsy is able to reflect the lymph node status of the entire axilla and starting from its introduction in the 1990s 5, 6 up to now, [7] [8] [9] [10] [11] [12] [13] [14] several studies have confirmed its outstanding effectiveness. Nonetheless, since this type of approach still has a level of invasiveness, however minimal, alternative methods have been tested over time to evaluate the axillary lymph node status without resorting to sentinel lymph node biopsy, even more so after the publication of the results of the Z0011 trial of the American College of Surgeons Oncology Group, 15 which showed how in a subpopulation of patients at an early stage of breast cancer, axillary clearance could be avoided even with a sentinel lymph node biopsy with positive results for micrometastasis. The debate over assessment of the node parameter for breast cancer is still very lively, leading to the search for a diagnostic method that is both effective and noninvasive. [16] [17] [18] Sonography, [19] [20] [21] color Doppler imaging, 22, 23 and elastography have been examined, even though their diagnostic accuracy indices are not generally high, hence the necessity of an in-depth analysis by means of ultrasound-guided fine-needle aspiration. 24, 25 The results thus obtained (although they do not reach the accuracy of a histologic study) are acceptable, but the problem of the invasiveness of the method has not been radically overcome.
Recently, to evaluate their diagnostic ability in this area, other techniques have been tested, such as positron emission sonography, positron emission sonography/ computed tomography, and magnetic resonance imaging. [26] [27] [28] [29] However, a newer sonographic modality has been available for some time now: contrast-enhanced sonography. Thanks to it, we can obtain reference points for the vascularization pattern of a given organ. The purpose of this study was to evaluate the diagnostic performance of contrast-enhanced sonography for characterization of the lymph node status (metastatic or not) in patients with breast carcinomas and to compare contrast-enhanced sonography with sentinel lymph node biopsy.
Materials and Methods
This research was conducted in compliance with the Declaration of Helsinki. The Institutional Ethical Committee of Azienda Ospedali Riuniti approved the study, and written informed consent was obtained from all patients participating in the study.
From January to August 2015, we prospectively and consecutively selected 50 female patients with a histologic diagnosis of invasive breast carcinoma. Before surgery, all patients were examined by axillary contrastenhanced sonography for characterization of axillary lymph nodes (on the same side of the tumor). For the target lymph node (ie, the one to be examined with contrast-enhanced sonography), we chose a node with a sonographic pattern that was suspicious for malignancy: a longitudinal-to-transverse diameter ratio of less than 2 (which suggests a round shape), absence of a central hyperechogenic hilum, or both. In cases with a lack of sonographic signs of malignancy, we evaluated the axillary lymph node with the maximal transverse diameter. Contrast-enhanced sonography was performed by a single radiologist, with 20 years of experience in sonography and 5 in contrast-enhanced sonography, using an iU22 ultrasound system with a 12-MHz, 38-mm high-resolution linear transducer (Philips Healthcare, Eindhoven, the Netherlands).
Contrast-enhanced sonography was performed with a second-generation contrast agent consisting of sulfur hexafluoride microbubbles (SonoVue; Bracco SpA, Milan, Italy); 2.4 mL (5 mg/mL) was administered by an intravenous bolus injection via a 21-gauge needle into a peripheral vein, followed by infusion of 5 mL of a saline solution at the same injection rate. Only a single bolus was administered to each patient. During the test, which was performed with a low mechanical index (0.05-0.20), the microbubbles could oscillate at their maximum intensity without being destroyed. Acquisition of contrast-enhanced sonograms was done with B-mode contrast-dedicated visualization software, which was able to selectively receive the signal emitted by the microbubbles, eliminating contemporaneously useless signals (contrast-tuned imaging)
The average duration of the test was about 60 seconds starting from the infusion of the contrast agent. We evaluated the contrast enhancement characteristics of each lymph node, both during the arterial phase (the first 5 seconds after the appearance of the contrast agent in the node) and during the parenchymal phase (the period between 6 and 20 seconds). Enhancement was classified as present or absent and homogeneous or heterogeneous. Nodes were considered malignant in cases with total absence of perfusion and in those with evidence of enhancement alterations, with perfusion defects located on the entire lymph node or on a portion of it, which was classified as heterogeneous enhancement. All patients then underwent Sentinel lymph node dissection (within 1 week of contrast-enhanced sonography), followed by a histologic test.
Results
The 50 patients were between 41 and 72 years old (mean age, 55 years). The primary tumor was invasive ductal carcinoma (64% of the cases), followed by invasive lobular carcinoma (32%) and poorly differentiated carcinoma (4%). The 50 detected axillary lymph nodes had a mean longitudinal diameter of 1.4 cm (largest diameter, 3 cm; smallest diameter, 1 cm) and a mean transverse diameter of 0.8 cm (largest diameter, 2 cm; smallest diameter, 0.3 cm).
The definitive histologic diagnoses showed benignity in 22 of the 50 sentinel lymph nodes, whereas 28 were sites of breast tumor metastasis. The lymph nodes evaluated as benign had largest longitudinal diameters of 9 to 13 mm (11 mm on average), and the malignant nodes has largest diameters of 8 to 30 mm (16 mm on average).
Contrast-enhanced sonography showed that among the 22 patients with negative biopsy results, 12 (55%) had a target lymph node with intense homogeneous enhancement ( Figures 1 and 2) ; 6 (27%) had a target lymph node with weak homogeneous enhancement; 4 (18%) had a target lymph node with intense heterogeneous enhancement (Figures 3 and 4) , and 0 had a target lymph node with weak heterogeneous enhancement. Among the 28 patients with positive biopsy results, contrast-enhanced sonography showed intense heterogeneous enhancement in 24 target lymph nodes (86%; Figures 5 and 6 ) and weak heterogeneous enhancement in the remaining 4 (14%); none showed intense homogeneous or weak homogeneous enhancement. No patient in either group showed complete absence of enhancement.
Considering homogeneous enhancement (be it intense or weak) as a sign of benignity and heterogeneous or completely absent enhancement as a sign of malignancy, among the 22 patients with negative biopsy results, we obtained 18 concordances (true-negative) and 4 false-positive results. On the contrary, among the 28 patients with positive biopsy results, we obtained 100% correct diagnoses. The sensitivity, specificity, and accuracy obtained by contrast-enhanced sonography for characterization of axillary lymph nodes were 100%, 82%, and 92%, respectively. The positive predictive value of contrast-enhanced sonography was 88%, whereas its negative predictive value was 100%.
Discussion
The effectiveness of sonography and color Doppler imaging for studying the axilla in patients with invasive breast neoplasms is controversial in the literature. Some studies 22, 23, 30 showed that these techniques, especially if combined, had good levels of sensitivity, specificity, and accuracy, although not comparable to biopsy. Some other works, even recently, 31 reported different results overall for the sensitivity. We tried to evaluate the impact of the use of contrast-enhanced sonography in this general context.
Since we cannot know which is the sentinel lymph node before the surgery, we made a comparison per patient instead of a per node once for each technique. Thus, we used contrast-enhanced sonography to examine lymph nodes that had features indicating malignancy on preliminary B-mode sonography. In cases with a lack of this kind of pattern in any axillary lymph node, we choose the one with the maximal transverse diameter, as seen in the literature. 30 Among the 50 patients analyzed, contrast-enhanced sonography confirmed the histologic diagnoses in 46 cases, with 4 false-positive results. These results are broadly similar to those reported by previous studies that investigated this method, 30 with some considerable differences.
Other authors have tried to introduce quantitative methods combined with direct investigation, using software to calculate the contrast enhancement intensity (especially peak intensity, time to peak intensity, and difference between highest and lowest contrastenhancement intensities recorded). On one hand, this approach attempts to define a technique that is reproducible and connected to qualitative data; on the other hand, the risk is making the procedure too complex and losing diagnostic accuracy. These studies show a lack of agreement about which quantitative method to use and a reduction in sensitivity and specificity rates compared to direct observation. From our experience, this last aspect should be given greater prominence while waiting for calculation software to provide more precise and efficient instruments. Another important element, with particular reference to a study by Ouyang et al, 30 is the attempt to correlate contrast enhancement characteristics with tumor aggressiveness, from the association with epidermal growth factor receptor 2 (HER-2/neu) expression by neoplastic cells. The above-mentioned study found a statistically significant association and hence a further element endorsing the use of contrastenhanced sonography for detecting lymph node metastasis in breast cancer.
What appears to be important in this study (and agreed on by the most recent studies on this topic 30 ) are the values for the sensitivity, specificity, and accuracy of contrast-enhanced sonography, which were 100%, 82%, and 92%, respectively. These values were considerably higher than those obtained by other sonographic techniques, [19] [20] [21] [22] [23] especially concerning sensitivity. Moreover, a specific aspect of our study needs to be pointed out: the ability of contrast-enhanced sonography to also identify 4 cases in which micrometastases were histologically detected among the malignant lymph nodes. This fact tells us about the ability of this technique to detect metastasis at an early stage.
Concerning the 4 false-positive results ( Figures 3  and 4) , we can say that one possible explanation for these results can be gathered from the necrosis phenomenon, which is a widely recognized malignancy parameter. However, necrosis can also result from inflammatory phenomena, as in granulomatous lymphadenitis. 
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Necrosis prevents homogeneous enhancement of the lymph node, which therefore shows a malignant pattern without actually corresponding to the presence of metastasis in the lymph node itself. This aspect is very important because it causes a reduction in the specific of contrast-enhanced sonography and appears to be a considerable limitation to its use in clinical routines. Another weak point of our study was the small number of patients included, which unfortunately does not allow more general observations to be drawn with reasonable certainty.
In conclusion, contrast-enhanced sonography of axillary lymph nodes appears to be a method with high diagnostic accuracy, which is not only superior to that of traditional sonographic techniques but also very close to that of the reference-standard sentinel lymph node biopsy. In our results, the sensitivity, in particular, reached 100%. The capacity of contrast-enhanced sonography to show micrometastasis of lymph nodes appears to also be relevant, which demonstrates that this technique is able to lead to an early diagnosis of locoregional lymph node invasion by breast carcinoma. The only specific weakness of this technique that our study found was its specificity, which was affected by the problem of necrosis, a phenomenon that is evaluated in the same way by contrast-enhanced sonography in both malignant and benign disease.
We can say that our study indicates that contrastenhanced sonography is a minimally invasive, easily repeatable method requiring a short execution time (even though the operator needs to have good manual skills and experience in evaluating contrast-enhanced imaging findings) and is able to give important information about lymph node vascularization. Our results were slightly different from those present in the literature, 30 and certainly, a weak point of our study was the small number of patients included. On the other hand, reports with higher numbers of patients cannot currently be found in the literature, and the latest studies dealing with the use of contrast-enhanced sonography have been focused on other possible uses, such as detecting sentinel lymph nodes by intradermal injections or in association with fine-needle aspiration techniques. 32, 33 In this context, our aim is to supply a new contribution to the debate over a technique that we consider potentially very powerful and to encourage multicenter studies that may finally confirm the validity of contrast-enhanced sonography in routine use (overall trying to increase specificity, for example, by improvements in contrast enhancement calculation software, which is not yet adequately effective). Moreover, if a technique for detecting sentinel lymph nodes with sonography is defined in the future (the literature shows the presence of some attempts done with intradermal microbubble injections 32 ), perhaps it would be possible to also exploit the accuracy of contrast-enhanced sonography in this area.
